Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Altundag
Kadri
K
Altundag
Ozden
O
Morandi
Paolo
P
Gunduz
Mehmet
M
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D000068877:Imatinib Mesylate; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009363:Neoplasm Proteins / Q000187:drug effects*; D010166:Palliative Care; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology*; D017479:Receptors, Platelet-Derived Growth Factor / Q000187:drug effects*; D017211:Treatment Failure; D000077211:Zoledronic Acid
D001549:Benzamides; D004164:Diphosphonates; D007093:Imidazoles; D009363:Neoplasm Proteins; D010879:Piperazines; D011743:Pyrimidines; D000077211:Zoledronic Acid; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor